Home › Funds › Crystal Cove Asset Management, LLC › MLTX
Crystal Cove Asset Management, LLC position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Crystal Cove Asset Management, LLC reported holding 10,000 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$117K, representing 0.25% of its reported portfolio and ranking #18 among its reported holdings. Crystal Cove Asset Management, LLC has disclosed MLTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-07 · Source: SEC EDGAR Form 13F-HR
How Crystal Cove Asset Management, LLC's MLTX position evolved
Crystal Cove Asset Management, LLC first disclosed a stake in MLTX in Q1 2026 at 10,000 shares (US$186K). The position peaked in Q2 2026 at 10,000 shares, worth US$195K. Across 3 filings, Crystal Cove Asset Management, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 10,000 shares valued at US$117K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 10.00K | $186.40K | New |
| Q2 2026 | 10.00K | $194.70K | Hold |
| Q3 2026 | 10.00K | $117.00K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 30 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on Crystal Cove Asset Management, LLC
FAQ
How long has Crystal Cove Asset Management, LLC held MLTX?
Crystal Cove Asset Management, LLC has disclosed MLTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Crystal Cove Asset Management, LLC's current position in MLTX?
As of Q3 2026, Crystal Cove Asset Management, LLC holds 10.00K shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $117.00K, representing 0.25% of its reported portfolio and ranking #18.
Has Crystal Cove Asset Management, LLC been buying or selling MLTX?
In the latest 13F filing (Q3 2026), Crystal Cove Asset Management, LLC held unchanged its position in MLTX. The position peaked in Q2 2026 at 10.00K shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.